CFGS
CYTK icon

Concourse Financial Group Securities’s Cytokinetics CYTK Stock Holding History

Concourse Financial Group Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$46 – 459
2024
Q4 		$46 Hold
1
– – ﹤0.01% 2228
2024
Q3 		$52 Hold
1
– – ﹤0.01% 2220
2024
Q2 		$54 Hold
1
– – ﹤0.01% 2277
2024
Q1 		$70 Hold
1
– – ﹤0.01% 2278
2023
Q4 		$83 Hold
1
– – ﹤0.01% 2244
2023
Q3 		$29 Buy
+1
New +$33 ﹤0.01% 2286

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Concourse Financial Group Securities's CYTK Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 1 share — an estimated $46 sold.

Concourse Financial Group Securities first reported a position in CYTK in Q3 2023 and held it in 6 quarters. The position peaked at $83 in Q4 2023. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 1 Cytokinetics share in Q1 2025, an estimated $46.
  • Concourse Financial Group Securities first reported a position in Cytokinetics in Q3 2023 and held it in 6 quarters.
  • Concourse Financial Group Securities's Cytokinetics position peaked at $83 in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.